Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India

BMJ Global Health
Itamar MegiddoRamanan Laxminarayan

Abstract

Pneumococcal pneumonia causes an estimated 105 000 child deaths in India annually. The planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is expected to avert child deaths, but the high cost of PCV relative to current vaccines provided under the Universal Immunization Programme has been a concern. Cost-effectiveness studies from high-income countries are not readily comparable because of differences in the distribution of prevalent serotypes, population and health systems. We extended IndiaSim, our agent-based simulation model representative of the Indian population and health system, to model the dynamics of Streptococcus pneumoniae. This enabled us to evaluate serotype and overall disease dynamics in the context of the local population and health system, an aspect that is missing in prospective evaluations of the vaccine. We estimate that PCV13 introduction would cost approximately US$240 million and avert US$48.7 million in out-of-pocket expenditures and 34 800 (95% CI 29 600 to 40 800) deaths annually assuming coverage levels and distribution similar to DPT (diphtheria, pertussis and tetanus) vaccination (~77%). Introducing the vaccine protects the population, especially the poorest wealth quint...Continue Reading

References

Feb 29, 2000·Epidemiology and Infection·R JebarajM C Steinhoff
Feb 1, 2003·Epidemiology and Infection·C L ColesJ M Tielsch
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Feb 26, 2005·Tropical Medicine & International Health : TM & IH·Amita JainShally Awasthi
Sep 29, 2007·Indian Journal of Medical Microbiology·R GoyalV Talwar
Nov 6, 2007·Indian Journal of Pediatrics·C WattalSuresh Gupta
Jun 6, 2009·Vaccine·Hanna Rinta-KokkoKari Auranen
Sep 15, 2009·Lancet·Katherine L O'BrienUNKNOWN Hib and Pneumococcal Global Burden of Disease Study Team
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Apr 23, 2010·Emerging Infectious Diseases·Gerwin D RodenburgArie van der Ende
Jul 1, 2010·Indian Journal of Pediatrics·Rupak DhakalB V Bhat
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
Jul 12, 2013·The New England Journal of Medicine·Marie R GriffinCarlos G Grijalva
Dec 1, 2011·International Health·Azadeh TasslimiAnushua Sinha
Dec 1, 2011·International Health·Mari M NakamuraAnushua Sinha
Aug 13, 2014·International Journal of Pediatric Otorhinolaryngology·Vedantam RupaGrace Rebekah
Aug 26, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TorresT Welte
Nov 12, 2014·The New England Journal of Medicine·Anne von GottbergUNKNOWN GERMS-SA Investigators
Apr 17, 2015·BMC Public Health·Samuel K PeasahAnand Krishnan

❮ Previous
Next ❯

Software Mentioned

R
IndiaSim

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.